Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 2Withdrawn 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Solid Tumors, Adult 1Lung Neoplasms 1Lung Diseases 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Bronchial Neoplasms 1

Interventions

pembrolizumab 115Carboplatin 103Pemetrexed 90Cisplatin 58Paclitaxel 47osimertinib 40Drug Therapy 40Nivolumab 39Docetaxel 35Specimen Handling 33Magnetic Resonance Spectroscopy 28Bevacizumab 26durvalumab 23Gemcitabine 22cemiplimab 21Radiotherapy 20130-nm albumin-bound paclitaxel 20Radiosurgery 19tislelizumab 18atezolizumab 17aflutinib 15Cetuximab 15Immunotherapy 14Immune Checkpoint Inhibitors 14Platinum Compounds 13Ipilimumab 13Biopsy 12Standard of Care 11Surgical Procedures, Operative 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Non-Small-Cell Lung × Toll-Like Receptor 1 × Clear all
NCT04614103 2026-04-15

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Iovance Biotherapeutics, Inc.

Phase 2 Recruiting
170 enrolled
Thoracic

Bronchial Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡